NCT02042872View on ClinicalTrials.gov

Zoledronic Acid Administration in Acute Spinal Cord Injury

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Disuse Osteoporosis
Interventions
DRUG

Zoledronic acid

At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.

Trial Locations (1)

07052

Kessler Institute for Rehabilitation, West Orange

All Listed Sponsors
collaborator

Kessler Institute for Rehabilitation

INDUSTRY

lead

James J. Peters Veterans Affairs Medical Center

FED

NCT02042872 - Zoledronic Acid Administration in Acute Spinal Cord Injury | Biotech Hunter | Biotech Hunter